Eloxx Pharmaceuticals, Inc. (ELOX) stock
ELOXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$12.75−0.40 (-3.04%)
Close on Nov 16, 2026Market cap $86.56MP/E –Yield –
Eloxx Pharmaceuticals EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Eloxx Pharmaceuticals's EPS for the twelve months ending Dec 31, 2023 was -$6.63. For fiscal 2025 it was -$0.49. The highest annual figure on record is -$0.49 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$0.49 | – |
| FY2024 | Dec 31, 2024 | -$0.84 | – |
| FY2023 | Dec 31, 2023 | -$6.63 | – |
| FY2022 | Dec 31, 2022 | -$16.65 | – |
| FY2021 | Dec 31, 2021 | -$38.15 | – |
| FY2020 | Dec 31, 2020 | -$34.40 | – |
| FY2019 | Dec 31, 2019 | -$53.60 | – |
| FY2018 | Dec 31, 2018 | -$58.00 | – |
| FY2016 | Jun 30, 2016 | -$16.80 | – |
| FY2015 | Jun 30, 2015 | -$52.40 | – |
| FY2014 | Jun 30, 2014 | -$101.20 | – |
| FY2013 | Jun 30, 2013 | -$204.40 | – |
| FY2012 | Jun 30, 2012 | -$312.40 | – |
| FY2011 | Jun 30, 2011 | -$560.00 | – |
| FY2010 | Jun 30, 2010 | -$2680.00 | – |
Quarterly eps
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | -$0.66 | – |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | -$0.08 | – |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -$5.45 | – |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -$0.45 | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -$0.92 | – |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -$1.31 | – |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -$1.96 | – |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -$2.88 | – |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | -$2.92 | – |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | -$3.47 | – |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | -$4.90 | – |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | -$5.36 | – |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | -$5.59 | – |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | -$4.40 | – |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | -$21.60 | – |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -$8.80 | – |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | -$6.10 | – |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | -$6.40 | – |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | -$8.00 | – |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | -$14.00 | – |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | -$11.61 | – |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | -$12.80 | – |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | -$16.00 | – |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | -$13.20 | – |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | -$15.90 | – |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | -$12.80 | – |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | -$16.80 | – |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | -$12.40 | – |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | -$2.27 | – |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | -$6.00 | – |
| Q2 FY2016CQ4 2015 | Dec 31, 2015 | -$7.60 | – |
| Q1 FY2016CQ3 2015 | Sep 30, 2015 | -$0.80 | – |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | -$4.26 | – |
| Q3 FY2015CQ1 2015 | Mar 31, 2015 | -$3.60 | – |
| Q2 FY2015CQ4 2014 | Dec 31, 2014 | -$31.20 | – |
| Q1 FY2015CQ3 2014 | Sep 30, 2014 | -$15.20 | – |
| Q4 FY2014CQ2 2014 | Jun 30, 2014 | -$20.72 | – |
| Q3 FY2014CQ1 2014 | Mar 31, 2014 | -$34.80 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?